Health Care & Life Sciences » Biotechnology | AC Immune

AC Immune S.A. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
3,327.10
76,445.60
149,761.40
127,631.60
189,147.90
Total Accounts Receivable
26,154.10
315.70
1,383.40
3,696.30
4,161.10
Other Current Assets
375.40
338.70
1,257.40
1,595.70
2,398.10
Total Current Assets
29,856.60
77,099.90
152,402.20
132,923.60
195,707
Net Property, Plant & Equipment
547.50
499.50
1,102.00
2,414.60
3,371.90
Total Investments and Advances
85.50
84.90
84.60
129.30
308.40
Other Assets
-
2,166.80
-
-
-
Total Assets
30,489.60
79,851.10
153,588.80
135,467.40
199,387.30
Accounts Payable
1,594.10
1,717.30
3,970.10
1,120.60
Other Current Liabilities
2,853.10
4,377.60
5,792.30
8,888.70
Total Current Liabilities
4,447.20
6,094.90
9,762.40
10,009.20
Long-Term Debt
-
-
-
405.30
Provision for Risks & Charges
2,425.40
2,784.20
3,736.90
5,054.90
Other Liabilities
-
-
-
101.60
Total Liabilities
6,872.60
8,879.10
13,499.30
15,571.10
Common Equity (Total)
23,617.00
70,972.00
140,089.50
119,896.40
Total Shareholders' Equity
23,617.00
70,972.00
140,089.50
119,896.40
Total Equity
23,617.00
70,972.00
140,089.50
119,896.40
Liabilities & Shareholders' Equity
30,489.60
79,851.10
153,588.80
135,467.40

About AC Immune

View Profile
Address
EPFL Innovation Park
Lausanne Basel-Landschaft (Basle Country) 1015
Switzerland
Employees -
Website http://www.acimmune.com
Updated 07/08/2019
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.